The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Novel Drug Delivery Systems Market Research Report 2024
Synopsis
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
The global Novel Drug Delivery Systems market was valued at US$ 24300 million in 2023 and is anticipated to reach US$ 27380 million by 2030, witnessing a CAGR of 1.7% during the forecast period 2024-2030.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
Report Scope
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
The global Novel Drug Delivery Systems market was valued at US$ 24300 million in 2023 and is anticipated to reach US$ 27380 million by 2030, witnessing a CAGR of 1.7% during the forecast period 2024-2030.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
Report Scope
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel Drug Delivery Systems Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liposomes
1.2.3 PEGylated Proteins & Polypeptides
1.2.4 Polymer Nanoparticle
1.2.5 Protein–drug Conjugates
1.2.6 Others
1.3 Market by Application
1.3.1 Global Novel Drug Delivery Systems Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinic
1.3.3 Cancer Treatment Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel Drug Delivery Systems Market Perspective (2019-2030)
2.2 Novel Drug Delivery Systems Growth Trends by Region
2.2.1 Global Novel Drug Delivery Systems Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Novel Drug Delivery Systems Historic Market Size by Region (2019-2024)
2.2.3 Novel Drug Delivery Systems Forecasted Market Size by Region (2025-2030)
2.3 Novel Drug Delivery Systems Market Dynamics
2.3.1 Novel Drug Delivery Systems Industry Trends
2.3.2 Novel Drug Delivery Systems Market Drivers
2.3.3 Novel Drug Delivery Systems Market Challenges
2.3.4 Novel Drug Delivery Systems Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel Drug Delivery Systems Players by Revenue
3.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2019-2024)
3.1.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2019-2024)
3.2 Global Novel Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Novel Drug Delivery Systems Revenue
3.4 Global Novel Drug Delivery Systems Market Concentration Ratio
3.4.1 Global Novel Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel Drug Delivery Systems Revenue in 2023
3.5 Novel Drug Delivery Systems Key Players Head office and Area Served
3.6 Key Players Novel Drug Delivery Systems Product Solution and Service
3.7 Date of Enter into Novel Drug Delivery Systems Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel Drug Delivery Systems Breakdown Data by Type
4.1 Global Novel Drug Delivery Systems Historic Market Size by Type (2019-2024)
4.2 Global Novel Drug Delivery Systems Forecasted Market Size by Type (2025-2030)
5 Novel Drug Delivery Systems Breakdown Data by Application
5.1 Global Novel Drug Delivery Systems Historic Market Size by Application (2019-2024)
5.2 Global Novel Drug Delivery Systems Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Novel Drug Delivery Systems Market Size (2019-2030)
6.2 North America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Novel Drug Delivery Systems Market Size by Country (2019-2024)
6.4 North America Novel Drug Delivery Systems Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel Drug Delivery Systems Market Size (2019-2030)
7.2 Europe Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Novel Drug Delivery Systems Market Size by Country (2019-2024)
7.4 Europe Novel Drug Delivery Systems Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel Drug Delivery Systems Market Size (2019-2030)
8.2 Asia-Pacific Novel Drug Delivery Systems Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Novel Drug Delivery Systems Market Size by Region (2019-2024)
8.4 Asia-Pacific Novel Drug Delivery Systems Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel Drug Delivery Systems Market Size (2019-2030)
9.2 Latin America Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Novel Drug Delivery Systems Market Size by Country (2019-2024)
9.4 Latin America Novel Drug Delivery Systems Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel Drug Delivery Systems Market Size (2019-2030)
10.2 Middle East & Africa Novel Drug Delivery Systems Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2019-2024)
10.4 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Novel Drug Delivery Systems Introduction
11.1.4 Amgen Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Novel Drug Delivery Systems Introduction
11.2.4 Teva Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Novel Drug Delivery Systems Introduction
11.3.4 Roche Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.3.5 Roche Recent Development
11.4 UCB (Union Chimique Belge)
11.4.1 UCB (Union Chimique Belge) Company Detail
11.4.2 UCB (Union Chimique Belge) Business Overview
11.4.3 UCB (Union Chimique Belge) Novel Drug Delivery Systems Introduction
11.4.4 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.4.5 UCB (Union Chimique Belge) Recent Development
11.5 Celgene
11.5.1 Celgene Company Detail
11.5.2 Celgene Business Overview
11.5.3 Celgene Novel Drug Delivery Systems Introduction
11.5.4 Celgene Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.5.5 Celgene Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Novel Drug Delivery Systems Introduction
11.6.4 Merck Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Detail
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Novel Drug Delivery Systems Introduction
11.7.4 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.7.5 Gilead Sciences Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Novel Drug Delivery Systems Introduction
11.8.4 Sanofi Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Novel Drug Delivery Systems Introduction
11.9.4 Pfizer Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Novel Drug Delivery Systems Introduction
11.10.4 Takeda Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.10.5 Takeda Recent Development
11.11 Bausch&Lomb
11.11.1 Bausch&Lomb Company Detail
11.11.2 Bausch&Lomb Business Overview
11.11.3 Bausch&Lomb Novel Drug Delivery Systems Introduction
11.11.4 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.11.5 Bausch&Lomb Recent Development
11.12 Samyang Biopharmaceuticals
11.12.1 Samyang Biopharmaceuticals Company Detail
11.12.2 Samyang Biopharmaceuticals Business Overview
11.12.3 Samyang Biopharmaceuticals Novel Drug Delivery Systems Introduction
11.12.4 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.12.5 Samyang Biopharmaceuticals Recent Development
11.13 Johnson & Johnson
11.13.1 Johnson & Johnson Company Detail
11.13.2 Johnson & Johnson Business Overview
11.13.3 Johnson & Johnson Novel Drug Delivery Systems Introduction
11.13.4 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.13.5 Johnson & Johnson Recent Development
11.14 TOLMAR
11.14.1 TOLMAR Company Detail
11.14.2 TOLMAR Business Overview
11.14.3 TOLMAR Novel Drug Delivery Systems Introduction
11.14.4 TOLMAR Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.14.5 TOLMAR Recent Development
11.15 Astellas
11.15.1 Astellas Company Detail
11.15.2 Astellas Business Overview
11.15.3 Astellas Novel Drug Delivery Systems Introduction
11.15.4 Astellas Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.15.5 Astellas Recent Development
11.16 AMAG Pharmaceuticals
11.16.1 AMAG Pharmaceuticals Company Detail
11.16.2 AMAG Pharmaceuticals Business Overview
11.16.3 AMAG Pharmaceuticals Novel Drug Delivery Systems Introduction
11.16.4 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.16.5 AMAG Pharmaceuticals Recent Development
11.17 AbbVie
11.17.1 AbbVie Company Detail
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Novel Drug Delivery Systems Introduction
11.17.4 AbbVie Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.17.5 AbbVie Recent Development
11.18 Dr Reddy
11.18.1 Dr Reddy Company Detail
11.18.2 Dr Reddy Business Overview
11.18.3 Dr Reddy Novel Drug Delivery Systems Introduction
11.18.4 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.18.5 Dr Reddy Recent Development
11.19 AstraZeneca
11.19.1 AstraZeneca Company Detail
11.19.2 AstraZeneca Business Overview
11.19.3 AstraZeneca Novel Drug Delivery Systems Introduction
11.19.4 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.19.5 AstraZeneca Recent Development
11.20 Aspen
11.20.1 Aspen Company Detail
11.20.2 Aspen Business Overview
11.20.3 Aspen Novel Drug Delivery Systems Introduction
11.20.4 Aspen Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.20.5 Aspen Recent Development
11.21 Acrotech Biopharma
11.21.1 Acrotech Biopharma Company Detail
11.21.2 Acrotech Biopharma Business Overview
11.21.3 Acrotech Biopharma Novel Drug Delivery Systems Introduction
11.21.4 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.21.5 Acrotech Biopharma Recent Development
11.22 TWi Pharmaceuticals
11.22.1 TWi Pharmaceuticals Company Detail
11.22.2 TWi Pharmaceuticals Business Overview
11.22.3 TWi Pharmaceuticals Novel Drug Delivery Systems Introduction
11.22.4 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2019-2024)
11.22.5 TWi Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
